CancerCONSOGNCT02501174
Study of Elderly Patients With Cancer and Seen in Consultation of Geriatric Oncology in the Nord Pas-de-Calais (CONSOG).
An observational study of Cancer, run by Centre Oscar Lambret at 15 sites in France.
Trial summary
The aim of this study is to establish a common geriatric oncology medical database. The patients concerned are the patients having benefited from a geriatric oncology consultation in one of the participating centres. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Cancer
- How many people
- 2,914 participants
- Where
- 15 sitesFrance
- Study dates
- Oct 2014to Sep 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Patients included are patients followed in one of the participating centres and not opposing the use of their medical data.
Who may be able to join
- Patient seen in consultation of geriatric oncology in one of the participating centres in Nord Pas-de-Calais.
- Age ≥ 65 years
- Patient having been informed and not opposing the computerized processing of its data.
Who cannot join
- Patient having opposed the use of its medical data.
Trial locations and contacts
15 sites in 1 country.
15 sites in 1 country
France15 sites
Centre Hospitalier d'Arras
Arras
Centre Hospitalier
Béthune, 62408
Centre Hospitalier
Boulogne-sur-Mer, 62200
Centre Hospitalier, Douai
Douai
Centre Hospitalier
Dunkirk, 59240
Hospitalier Le Cateau-Cambresis
Le Cateau-Cambrésis
Polyclinique de Riaumont
Liévin, 62800
CHRU de Lille
Lille, 59000
Hôpital Saint Vincent de Paul
Lille, 59000
Centre Oscar Lambret
Lille, 59020
Hôpital Saint-Philibert
Lomme, 59160
Clinique Saint Jean, Roubaix
Roubaix
Centre Hospitalier
Tourcoing, 59200
Centre de cancérologie Les Dentellières
Valenciennes, 59300
Centre Hospitalier
Valenciennes, 59300
About this study
The aim of this study is to establish a common geriatric oncology medical database. The patients concerned are the patients having benefited from a geriatric oncology consultation in one of the participating centres. This database is designed with a view on the one hand to better describe to better understand this population and on the other hand to facilitate the conduct of future retrospective or prospective studies on this population. The constitution of this observatory of patients seen in consultation should facilitate the development of studies from the analysis of data collected, and occasional surveys by the rapid identification of cases. Data from this database could provide clinicians with valuable informative elements of descriptive epidemiology and concerning the organization of care in the geriatric oncology field.
Read the detailed description
The study is presented during the first consultation of oncogeriatric care or after this consultation (for patients having benefited from the consultation between January 2014 and October 2014) : the patient is informed with an information note and is told that he can express its opposition to the use of its clinical data. In case of no opposition from the patient, the referent geriatrician will complete the patient form with the requested data and will forward it for computerized processing.
- Conditions
- Cancer
- Keywords
- Geriatric oncology
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Measurement of the prevalence of different clinical criteria of interest : demographic characteristics, disease state, patient status according to the geriatric criteria (Comprehensive Geriatric Assessment (CGA)).
Measured: Up to 5 years
Secondary outcomes (4)
Measurement of the prevalence of different medical and social criteria of interest.
Patient's life characteristics (place of living, isolation) and the helps set up (presence of a natural caregiver, sources of professional help).
Measured: Up to 5 years
Measurement of the association between one or more factors of interest (clinical, biological and medical and social) related to a proposal to amend or not the initially proposed therapeutic strategy.
Measured: Up to 5 years
Percentage of patients included in trials.
Measured: Up to 5 years
Temporal evolutions of clinical, medical and social characteristics.
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2015 (estimated)
- Study startOct 2014
- Primary completionSep 2019
- Study completionSep 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 2,914 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Oscar Lambret
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Cédric GAXATTE, MD, Principal investigator, CHRU de Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02501174
- Sponsor's protocol ID
- CONSOG-1401
- Acronym
- CONSOG
- Status last verified
- Mar 2026
- First submitted
- 2 Jul 2015
- Last updated
- 18 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Elderly Patients With Cancer and Seen in Consultation of Geriatric Oncology in the Nord Pas-de-Calais (CONSOG).
- ClinicalTrials.gov ID
- NCT02501174
- Acronym / sponsor ID
- CONSOG / CONSOG-1401
- Conditions
- Cancer
- Keywords
- Geriatric oncology
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,914 participants (actual)
- Lead sponsor
- Centre Oscar LambretUniversity, hospital or other
- Study start
- Oct 2014 (actual)
- Primary completion
- Sep 2019 (actual)
- Study completion
- Sep 2019 (actual)
- First posted
- 17 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to establish a common geriatric oncology medical database. The patients concerned are the patients having benefited from a geriatric oncology consultation in one of the participating centres. This database is designed with a view on the one hand to better describe to better understand this population and on the other hand to facilitate the conduct of future retrospective or prospective studies on this population. The constitution of this observatory of patients seen in consultation should facilitate the development of studies from the analysis of data collected, and occasional surveys by the rapid identification of cases. Data from this database could provide clinicians with valuable informative elements of descriptive epidemiology and concerning the organization of care in the geriatric oncology field.
Detailed description
The study is presented during the first consultation of oncogeriatric care or after this consultation (for patients having benefited from the consultation between January 2014 and October 2014) : the patient is informed with an information note and is told that he can express its opposition to the use of its clinical data. In case of no opposition from the patient, the referent geriatrician will complete the patient form with the requested data and will forward it for computerized processing.
Study design
- Observational model
- Case only
- Time perspective
- Other
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Patients included are patients followed in one of the participating centres and not opposing the use of their medical data.
Key inclusion criteria (3 listed)
- Patient seen in consultation of geriatric oncology in one of the participating centres in Nord Pas-de-Calais.
- Age ≥ 65 years
- Patient having been informed and not opposing the computerized processing of its data.
Key exclusion criteria (1 listed)
- Patient having opposed the use of its medical data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Measurement of the prevalence of different clinical criteria of interest : demographic characteristics, disease state, patient status according to the geriatric criteria (Comprehensive Geriatric Assessment (CGA)).
Time frame: Up to 5 years
4 secondary outcomes
Measurement of the prevalence of different medical and social criteria of interest.
Time frame: Up to 5 years
Measurement of the association between one or more factors of interest (clinical, biological and medical and social) related to a proposal to amend or not the initially proposed therapeutic strategy.
Time frame: Up to 5 years
Percentage of patients included in trials.
Time frame: Up to 5 years
Temporal evolutions of clinical, medical and social characteristics.
Time frame: Up to 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cédric GAXATTE, MD principal investigator
CHRU de Lille
15 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Centre Oscar Lambret at 15 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 15 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measurement of the prevalence of different clinical criteria of interest : demographic characteristics, disease state, patient status according to the geriatric criteria (Comprehensive Geriatric Assessment (CGA)). (time frame: Up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026; AzTrials last refreshed its copy on 8 Nov 2026.